blood

Resumption of January 18 Sales Ban for Apple Watch Series 9 and Ultra 2 Models

Apple Watch Ultra 2 03
Apple Watch Series 9 and Apple Watch Ultra 2 sales will be halted again in the U.S. starting at 5 PM tomorrow, January 18, due to the rejection of a bid by Apple to have the sales ban paused throughout its appeal of an ITC decision that found its blood oxygen feature infringe on patents by medical tech company Masimo. Meanwhile, Apple has another route available to avoid a halt: U.S. Customs said earlier in the week that it would consider a software update that disabled Apple Watch blood oxygen sensing features to put the devices beyond the scope of the ITC ban, which means the company could effectively keep selling them if it pushes a firmware update to turn off all the pulse oximetry stuff. Apple’s appeal will still continue, however, and this doesn’t mean they won’t eventually win that, which would allow for a resumption of sale with the blood oxygen features included. It’ll be interesting to see what happens tomorrow when that 5 PM ET deadline hits. For those keeping track, this means the current Apple Watch models have now been removed from sale, resumed sales, and are pending another sales stoppage, all in under a month.

“Expanding AI Technology in Human Oncology: The Mission of ImpriMed, a Revolutionary Dog Cancer Treatment”

Gettyimages 1397710182
ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most suitable drugs for individual canine and feline blood cancers. The startup, which centers on improving treatment outcomes of dogs and cats with cancer first, now aims to expand its precision medicine technology for human oncology applications. “Also, the proven know-how acquired from developing AI algorithms in veterinary oncology streamlines the building of new predictive models in human oncology. For human precision oncology, its AI software for multiple myeloma, a rare blood cancer, is in the process of approval, aiming to commercialize in 2025, Lim told TechCrunch. ImpriMed’s unique strength is “the ability to develop and incorporate AI models into the personalized medicine service workflow,” according to Lim.